PepGen Inc. (PEPG) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for PEPG in the last 30 days. The most recent was published Aug 6, 2026.
PEPG rankings
Financial highlights
Full financials- Net income, TTM
- -$71.94M
- Free cash flow, TTM
- -$69.46M
- Cash
- $22.76M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks250%
2026-05-102026-11-01
Mix490d
- Other2(50%)
- SEC Filings2(50%)
Latest news
25 items- SECPepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- PRPepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg – – 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November – – Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 – – Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological di
- SECSEC Form 10-Q filed by PepGen Inc.10-Q - PepGen Inc. (0001835597) (Filer)
- PRPepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review– DSMB also recommended dose escalation in FREEDOM-OLE from 5 mg/kg to 10 mg/kg – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that an independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into the third and highest multiple ascending dose (MAD) cohort of 12.5 mg/kg, with no recommended changes to the study protocol. The DSMB also recommended dose escalation in the
- PRKalaris Appoints Laurie Keating to Board of DirectorsBERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In conjunction with the announcement of Ms. Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board of Directors. "We’re delighted to welcome Laurie to the Kalaris Board of Directors. She has extensive strategic, operational, and legal expertise spanning multiple therapeutic areas and development stages. Laurie will be
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - PepGen Inc. (0001835597) (Issuer)
- SECPepGen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PepGen Inc. (0001835597) (Filer)
- INSIDERSEC Form 4 filed by Director Wyman Lisa4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Resnick Joshua4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Mayer Howard4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Finer Mitchell H.4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Dable Habib J4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Henson Heidi4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Keating Laurie4 - PepGen Inc. (0001835597) (Issuer)
- ANALYSTCraig Hallum initiated coverage on PepGen with a new price targetCraig Hallum initiated coverage of PepGen with a rating of Buy and set a new price target of $11.00
- INSIDERChief Technical Officer Kasraian Kasra sold $1,739 worth of shares (1,233 units at $1.41) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 50,074 units (SEC Form 4) (withholding tax)4 - PepGen Inc. (0001835597) (Issuer)
- SECSEC Form EFFECT filed by PepGen Inc.EFFECT - PepGen Inc. (0001835597) (Filer)
- SECPepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - PepGen Inc. (0001835597) (Filer)
- PRPepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 ProgramPepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic dystrophy type 1 (DM1).
- SECSEC Form S-3 filed by PepGen Inc.S-3 - PepGen Inc. (0001835597) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)
- SECPepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- SECSEC Form 10-Q filed by PepGen Inc.10-Q - PepGen Inc. (0001835597) (Filer)
- PRPepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 – – Well-funded with $132.3M of cash as of March 31, 2026, sufficient to fund operations through FREEDOM2 12.5 mg/kg MAD readout and into 2H 2027 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights f
PEPG FAQ
10 questionsWhat does PepGen Inc. do?
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is...What is the latest news on PEPG?
Quantisnow has not tracked any new filings, ratings or press releases for PEPG in the last 30 days. The most recent wire item was published on August 6, 2026.Is PEPG profitable?
No. PepGen Inc. reported a net loss of $71.94M for the twelve months ended Jun 30, 2026.How much cash and debt does PEPG have?
PepGen Inc. reported $22.76M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PEPG stock trade?
PepGen Inc. (PEPG) is listed on NASDAQ.What sector and industry is PEPG in?
PepGen Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PepGen Inc. go public?
PepGen Inc. (PEPG) completed its IPO in 2022.What are analysts saying about PEPG?
Across the last 5 analyst actions on PepGen Inc., there were 0 upgrades and 2 downgrades. The most recent action was from Craig Hallum: Buy with a $11.00 price target on 2026-06-16.What companies are similar to PEPG?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PEPG side-by-side with any of them on Quantisnow.How can I track PEPG on Quantisnow?
Quantisnow aggregates PepGen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PEPG to receive live email and push alerts on every new disclosure.